The angiome: A new concept in cancer biology

Journal of Clinical Pathology

Volumn 64, Issue 7, 2011, Pages 637-643

  Blann, A D ^a   Ramcharan, K S ^a,b   Stonelake, P S ^b   Luesley, D ^c   Lip, G Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GROWTH FACTOR; VON WILLEBRAND FACTOR;

ANGIOGENESIS; CELL FUNCTION; CYTOLOGY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PULSE WAVE; REVIEW; STEM CELL; TUMOR CELL; TUMOR EMBOLISM; VASCULAR BIOLOGY;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 79959341679     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2011.088948     Document Type: Review

References (137)

1. Nikitenko LL. Vascular endothelium in cancer. Cell Tissue Res 2009;335:223-40.
2. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102-11. (Pubitemid 40127638)
3. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007;8:464-7.
4. Ocak I, Baluk P, Barrett T, et al. The biologic basis of in vivo angiogenesis imaging. Front Biosci 2007;12:3601-16.
5. Lin PC. Optical imaging and tumor angiogenesis. J Cell Biochem 2003;90:484-91. (Pubitemid 37243695)
6. Langenkamp E, Molema G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res 2009;335:205-22.
7. Mancuso P, Calleri A, Cassi C, et al. Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003;522:83-97. (Pubitemid 36570529)
8. Kobayashi H, Lin PC. Angiopoietin/Tie2 signaling, tumor angiogenesis and inflammatory diseases. Front Biosci 2005;10:666-74.
9. Mukhopadhyay D, Zeng H, Bhattacharya R. Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling. Mol Cell Biochem 2004;264:51-61.
10. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74. (Pubitemid 43093963)
11. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol 2002;34:1508-12.
12. Deanfield J, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115:1285-95. (Pubitemid 46594773)
13. Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 2003;348:1483-5. (Pubitemid 36407180)
14. Gaugler MH. A unifying system: does the vascular endothelium have a role to play in multi-organ failure following radiation exposure? BJR Suppl 2005;27:100-5.
15. Blann AD. Assessment of endothelial dysfunction: focus on atherothrombotic disease. Pathophysiol Haemost Thromb 2004;33:256-61.
16. Jaffe EA. Cell biology of endothelial cells. Hum Pathol 1987;18:234-8.
17. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995;90:244-8.
18. Banks RE, Gearing AJ, Hemingway IK, et al. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer 1993;68:122-4. (Pubitemid 23178563)
19. Byrne GJ, Ghellal A, Iddon J, et al. Serum soluble vascular cell adhesion molecule-1: role as surrogate marker of angiogenesis. J Natl Cancer Inst 2000;92:1329-36. (Pubitemid 30660593)
20. Pigott R, Dillon LP, Hemingway IH, et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992;187:584-9.
21. Steegmaier M, Levinovitz A, Isenmann S, et al. The E-selectin-ligand (ESL-1) is a variant of a receptor for fibroblast growth factor. Nature 1995;373:615-20.
22. Dimitroff CJ, Lee JY, Rafii S, et al. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001;153:1277-86. (Pubitemid 34289265)
23. Gout S, Morin C, Houle F, et al. Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res 2006;66:9117-24. (Pubitemid 44521131)
24. Barthel SR, Gavino JD, Descheny L, et al. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 2007;11:1473-91. (Pubitemid 350200482)
25. Wittig BM, Kaulen H, Thees R, et al. Elevated serum E-selectin in patients with liver metastases of colorectal cancer. Eur J Cancer 1996;32A:1215-18.
26. Koch AE, Halloran MM, Haskell CJ, et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995;376:517-19.
27. Sheen-Chen SM, Eng HL, Huang CC, et al. Serum levels of soluble E-selectin in women with breast cancer. Br J Surg 2004;91:1578-81.
28. Hebbar M, Révillion F, Louchez MM, et al. The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer. Clin Cancer Res 1998;4:373-80. (Pubitemid 28122752)
29. Braybrooke JP, O'Byrne KJ, Propper DJ, et al. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res 2000;6:4697-704. (Pubitemid 32110407)
30. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006;95:49-55.
31. Gralnick HR. Von Willebrand factor, integrins, and platelets: their role in cancer. J Lab Clin Med 1992;119:444-7.
32. Ablin RJ, Bartkus JM, Gonder MJ. Immunoquantitation of factor VIII-related antigen (von Willebrand factor antigen) in prostate cancer. Cancer Lett 1988;40:283-9.
33. Damin DC, Rosito MA, Gus P, et al. Von Willebrand factor in colorectal cancer. Int J Colorectal Dis 2002;17:42-5. (Pubitemid 41398990)
34. Facchini V, Gadducci A, Baicchi U, et al. Factor VIIIR: Ag plasma levels in patients with cervical and ovarian carcinoma. Eur J Gynaecol Oncol 1988;9:87-93. (Pubitemid 18038037)
35. Sweeney JD, Killion KM, Pruet CF, et al. Von Willebrand factor in head and neck cancer. Cancer 1990;11:2387-9.
36. Paczuski R, Bialkowska A, Kotschy M, et al. Von Willebrand factor in plasma of patients with advanced stages of larynx cancer. Thromb Res 1999;95:197-200. (Pubitemid 29415771)
37. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumour adhesion in vitro and metastasis in vivo. Thromb Haemost 1995;74:282-90.
38. Lackner C, Jukic Z, Tsybrovskyy O, et al. Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchow Arch 2004;445:160-7. (Pubitemid 39215547)
39. Floyd CM, Irani K, Kind PD, et al. Von Willebrand factor interacts with malignant hematopoietic cell lines: evidence for the presence of specific binding sites and modification of von Willebrand factor structure and function. J Lab Clin Med 1992;119:467-76.
40. Homoncik M, Blann AD, Hollenstein U, et al. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000;111:1250-2. (Pubitemid 32104947)
41. Reiter RA, Varadi K, Turecek PL, et al. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005;93:554-8. (Pubitemid 40392546)
42. Prizment AE, Anderson KE, Visvanathan K, et al. Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 2011;20:297-307.
43. Brown DJ, Milroy R, Preston T, et al. The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol 2007;60:705-8. (Pubitemid 46975230)
44. Firbas C, Siller-Matula JM, Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther 2010;8:1689-701.
45. Goon PK, Lip GY, Boos CJ, et al. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006;8:79-88.
46. Hladovec J, Jirka J, Prerovský I, et al. Decrease of endothelaemia during immunosuppression. Biomedicine 1976;25:204-6.
47. Mutin M, Canavy I, Blann A, et al. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999;93:2951-8. (Pubitemid 29200786)
48. Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-61.
49. Woywodt A, Streiber F, de Groot K, et al. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003;361:206-10. (Pubitemid 36126220)
50. Woywodt A, Goldberg C, Scheer J, et al. An improved assay for enumeration of circulating endothelial cells. Ann Hematol 2004;83:491-4. (Pubitemid 39144748)
51. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7. (Pubitemid 27087709)
52. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998;92:362-7. (Pubitemid 28323695)
53. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004;8:498-508. (Pubitemid 44145482)
54. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343-53. (Pubitemid 39100452)
55. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008;28:1584-95.
56. Timmermans F, Plum J, Yöder MC, et al. Endothelial progenitor cells: identity defined? J Cell Mol Med 2009;13:87-102.
57. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8. (Pubitemid 29377293)
58. Jiang M, Wang B, Wang C, et al. Angiogenesis by transplantation of HIF-1 alpha modified EPCs into ischemic limbs. J Cell Biochem 2008;103:321-34.
59. Bagley RG, Walter-Yohrling J, Cao X, et al. Endothelial precursor cells as a model of tumour endothelium: characterization and comparison with mature endothelial cells. Cancer Res 2003;63:5866-73. (Pubitemid 37187486)
60. Ahn GO, Brown JM. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis 2009;12:159-64.
61. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-201. (Pubitemid 33063774)
62. Seppä ST, Seppä HE, Liotta LA, et al. Cultured tumor cells produce chemotactic factors specific for endothelial cells: a possible mechanism for tumor-induced angiogenesis. Invasion Metastasis 1983;3:139-50. (Pubitemid 13018984)
63. Meininger CJ, Brightman SE, Kelly KA, et al. Increased stem cell factor release by hemangioma-derived endothelial cells. Lab Invest 1995;72:166-73.
64. Aonuma M, Saeki Y, Akimoto T, et al. Vascular endothelial growth factor overproduced by tumour cells acts predominantly as a potent angiogenic factor contributing to malignant progression. Int J Exp Pathol 1999;80:271-81.
65. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
66. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996;2:821-6. (Pubitemid 26168934)
67. Dirix LY, Vermeulen PB, Pawinski A, et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997;76:238-43. (Pubitemid 27279665)
68. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-61. (Pubitemid 24076875)
69. Moore MA, Hattori K, Heissig B, et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 2001;938:36-45.
70. Burger PE, Coetzee S, McKeehan WL, et al. Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells. Blood 2002;100:3527-35. (Pubitemid 35303920)
71. Kumar H, Heer K, Greenman J, et al. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res 2002;22:1877-80. (Pubitemid 34839213)
72. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
73. Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
74. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signalling is required for vascular homeostasis. Cell 2007;130:691-703. (Pubitemid 47268059)
75. Loges S, Mazzone M, Hohensinner P, et al. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009;15:167-70.
76. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumour angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40.
77. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-25. (Pubitemid 32176299)
78. Poon RT, Ho JW, Tong CS, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004;91:1354-60. (Pubitemid 39331462)
79. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469-78. (Pubitemid 44714526)
80. Aref S, El Sherbiny M, Goda T, et al. Soluble VEGF/ sFLt1 ratio is an independent predictor of AML patient outcome. Hematology 2005;10:131-4. (Pubitemid 41800786)
81. Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye (Lond) 2008;22:1330-6.
82. Karim R, Tang B. Use of antivascular endothelial growth factor for diabetic macular edema. Clin Ophthalmol 2010;4:493-517.
83. Nakagawa T, Kosugi T, Haneda M, et al. Abnormal angiogenesis in diabetic nephropathy. Diabetes 2009;58:1471-8.
84. Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol 2000;50:397-404.
85. Corretti MC, Anderson TJ, Benjamin EJ, et al; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65. (Pubitemid 34084631)
86. Stout M. Flow-mediated dilatation: a review of techniques and applications. Echocardiography 2009;26:832-41.
87. Vassilakopoulou M, Mountzios G, Papamechael C, et al. Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrogen-mediated vasodilatation. Vascul Pharmacol 2010;53:115-21. [Epub ahead of print].
88. Wilkinson IB, Hall IR, MacCallum H, et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002;22:147-52. (Pubitemid 34076246)
89. Naka KK, Tweddel AC, Doshi SN, et al. Flow-mediated changes in pulse wave velocity: a new clinical measure of endothelial function. Eur Heart J 2006;27:302-9. (Pubitemid 43100025)
90. Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004;44:2137-41. (Pubitemid 39576032)
91. Dobson G, Chong M, Walker M, et al. Characterization of the upper limb arterial properties during reactive hyperemia. Cardiovasc Eng 2007;7:127-34. (Pubitemid 47487736)
92. Hayward CS, Kraidly M, Webb CM, et al. Assessment of endothelial function using peripheral waveform analysis: a clinical application. J Am Coll Cardiol 2002;40:521-8. (Pubitemid 34833170)
93. Ogawa S. MRI of blood vessels at high fields: in vivo and in vitro measurements and image simulation. Magn Reson Med 1990;16:9-18. (Pubitemid 20353794)
94. Pathak AP, Gimi B, Glunde K, et al. Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol 2004;386:3-60. (Pubitemid 38657586)
95. Pathak AP, Hochfeld WE, Goodman SL, et al. Circulating and imaging markers for angiogenesis. Angiogenesis 2008;11:321-35.
96. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer 2008;8:94-107. (Pubitemid 351161320)
97. Artemov D. Molecular magnetic resonance imaging with targeted contrast agents. J Cell Biochem 2003;90:518-24. (Pubitemid 37243699)
98. McLarty K, Reilly RM. Molecular imaging as a tool for personalized and targeted anticancer therapy. Clin Pharmacol Ther 2007;81:420-4. (Pubitemid 46364494)
99. Bossi P, Viale G, Lee AK, et al. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 1995;55:5049-53.
100. Ellis LM, Takahashi Y, Fenoglio CJ, et al. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998;34:337-40. (Pubitemid 28183830)
101. Igarashi M, Dhar DK, Kubota H, et al. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer 1998;82:1225-32. (Pubitemid 28155382)
102. Taylor AP, Rodriguez M, Adams K, et al. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer 2003;105:158-64. (Pubitemid 36505315)
103. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-9. (Pubitemid 46657433)
104. Fürstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006;94:524-31. (Pubitemid 43289756)
105. Beerepoot LV, Mehra N, Vermaat JS, et al. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 2004;15:139-45. (Pubitemid 38139616)
106. Caine GJ, Ryan P, Lip GY, et al. Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients. Cancer Lett 2007;251:296-301. (Pubitemid 46669799)
107. Gil-Bazo I, Catalán Goni V, Alonso Gutiérrez A, et al. Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. Clin Transl Oncol 2005;7:150-5.
108. Gadducci A, Baicchi U, Marrai R, et al. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecol Oncol 1994;53:352-6. (Pubitemid 24187865)
109. Amis SJ, Coulter-Smith SD, Crow JC, et al. Microvessel quantification in benign and malignant ovarian tumors. Int J Gynecol Cancer 2005;15:58-65. (Pubitemid 40194334)
110. Hata K, Fujiwaki R, Nakayama K, et al. Expression of thymidine phosphorylase and VEGF in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor. Anticancer Res 2000;20:3941-9. (Pubitemid 32002302)
111. Hartenbach EM, Olson TA, Goswitz JJ, et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997;121:169-75. (Pubitemid 28008916)
112. Artini PG, Cristello F, Monti M, et al. VEGF and its soluble receptor in ovarian pathology. Gynecol Endocrinol 2005;21:50-6.
113. Hata K, Nakayama K, Fujiwaki R, et al. Expression of the angopoietin-1, angopoietin-2, Tie2, and VEGF gene in epithelial ovarian cancer. Gynecol Oncol 2004;93:215-22. (Pubitemid 38429573)
114. Zhang L, Yang N, Park JW, et al. Tumor-derived VEGF up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003;63:3403-12. (Pubitemid 36735901)
115. Hata K, Udagawa J, Fujiwaki R, et al. Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology 2002;62:340-8. (Pubitemid 34914103)
116. Alvarez AA, Krigman HR, Whitaker RS, et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999;5:587-91. (Pubitemid 29131968)
117. Abulafia O, Triest WE, Sherer DM. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 1997;177:541-7. (Pubitemid 27413766)
118. Monk BJ, Choi DC, Pugmire G, et al. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005;96:902-5. (Pubitemid 40255525)
119. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-77. (Pubitemid 41502830)
120. Moore RG, Maclaughlan S. Current clinical use of biomarkers for epithelial ovarian cancer. Curr Opin Oncol 2010;22:492-7. [Epub ahead of print].
121. Xing W, Zhigang W, Bing H, et al. Targeting an ultrasound contrast agent to folate receptors on ovarian cancer cells: feasibility research for ultrasonic molecular imaging of tumor cells. J Ultrasound Med 2010;29:609-14.
122. Kosaka N, Ogawa M, Paik DS, et al. Semiquantitative assessment of the microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer. Cancer Sci 2010;101:820-5.
123. Brooks RA, Powell MA. Novel imaging modalities in gynecologic cancer. Curr Oncol Rep 2009;11:466-72.
124. Prakash P, Cronin CG, Blake MA. Role of PET/CT in ovarian cancer. Am J Roentgenol 2010;194:W464-70.
125. Su Y, Zheng L, Wang Q, et al. Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer. J Exp Clin Cancer Res 2010;29:27.
126. Annunziata CM, Walker AJ, Minasian L, et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 2010;16:664-72.
127. Stadler WM, Cao D, Vogelzang NJ, et al. A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 2004;10:3365-70. (Pubitemid 38685441)
128. Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targetting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24:1491-8. (Pubitemid 46638769)
129. Staton CA, Reed MW, Brown NJ. A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol 2009;90:195-221.
130. Gasparini G. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 2001;37:97-114. (Pubitemid 32106909)
131. Ruegg C, Meuwly JY, Driscoll R, et al. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med 2003;3:673-91. (Pubitemid 37536874)
132. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
133. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)
134. Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13:2643-50. (Pubitemid 46788031)
135. Pircher A, Kähler CM, Skvortsov S, et al. Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance. Oncol Rep 2008;19:345-52. (Pubitemid 351176093)
136. Yu D, Sun X, Qiu Y, et al. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res 2007;13:3814-24. (Pubitemid 47037586)
137. Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011;117:1071-80.